Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / February 24, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported...
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint NeuroRx to File for Emergency Use Authori...
Relief Therapeutics (RLFTF) and partner NeuroRx announce preliminary results from the Phase 2b/3 trial of intravenously administered RLF-100 (aviptadil). The data suggest that intravenous RLF-100 could reduce the length of hospital stay among patients with respiratory failure due to critical ...
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment Specifical...
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment...
GENEVA, SWITZERLAND / ACCESSWIRE / February 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief " or the " Company ") announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt. Mr. Burckhardt has resigned to focus his time and effo...
Relief Therapeutics (RLFTF) affirms that its partner NeuroRx has initiated a phase 2/3 clinical trial investigating inhaled RLF-100 (aviptadil; Zyesami) for the treatment of severe COVID-19 in partnership with UCI Health of the University of California, Irvine.The objective of ...
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaboration and license agreement by June 30, 2021 GENEVA and NEWTON, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE)...
Relief Therapeutics (RLFTF) and Acer Therapeutics (ACER) have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001.ACER-001 (sodium phenylbutyrate) powder is a t...
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaboration and license agreement by June 30, 2021 GENEVA, SWITZERLAND, and NEWTON, MA / ACCESSWIRE / January 25, 2021 / R...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Repo...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announce...